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Reduced capacity of tumour blood vessels to produce endothelium-derived
relaxing factor: significance for blood flow modification
GM Tozer, VE Prise, KM Bell, MF Dennis, MRL Stratford and DJ Chaplin
Tumour Microcirculation Group, Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, Middlesex HA6
2JR, UK.
Summary The effect of nitric oxide-dependent vasodilators on vascular resistance of tumours and normal
tissue was determined with the aim of modifying tumour blood flow for therapeutic benefit. Isolated
preparations of the rat P22 tumour and normal rat hindlimb were perfused ex vivo. The effects on tissue
vascular resistance of administration of sodium nitroprusside (SNP) and the diazeniumdiolate (or NONO-ate)
NOC-7, vasodilators which act via direct release of nitric oxide (NO), were compared with the effects of
acetylcholine (ACh), a vasodilator which acts primarily via receptor stimulation of endothelial cells to release
NO in the form of endothelium-derived relaxing factor (EDRF). SNP and NOC-7 effectively dilated tumour
blood vessels after preconstriction with phenylephrine (PE) or potassium chloride (KCI) as indicated by a
decrease in vascular resistance. SNP also effectively dilated normal rat hindlimb vessels after PE/KC1
constriction. Vasodilatation in the tumour preparations was accompanied by a significant rise in nitrite levels
measured in the tumour effluent. ACh induced a significant vasodilation in the normal hindlimb but an
anomalous vasoconstriction in the tumour. This result suggests that tumours, unlike normal tissues are
incapable of releasing NO (EDRF) in response to ACh. Capacity for EDRF production may represent a
difference between tumour and normal tissue blood vessels, which could be exploited for selective
pharmacological manipulation of tumour blood flow.
Keywords: P22 rat carcinosarcoma; tumour vascular resistance; nitric oxide; nitric oxide donors; isolated
perfusion; endothelium-derived relaxing factor
Selective pharmacological manipulation of tumour blood
flow has potential for improving various therapeutic
modalities. Many different classes of vasoactive agents have
been tested in tumours and the results have been reviewed
previously (Jain and Ward-Hartley, 1984; Sagar et al., 1993).
Nitric oxide (NO) is well recognised as a primary determinant
of normal tissue vasodilatory tone, but its role in the
maintenance of vascular tone in tumours is poorly under-
stood. Any differences in NO production or function in a
tumour microenvironment would provide a means for
selective tumour blood flow modification.
Various vasodilators, such as acetylcholine (ACh) and
bradykinin, require an intact endothelium to dilate vascular
smooth muscle. The requirement for release of an
endothelium-derived relaxing factor (EDRF) to elicit ACh-
induced vasodilation was first demonstrated by Furchgott
and Zawadzki (1980). Nitric oxide (NO) is now recognised as
the primary EDRF mediating vascular smooth muscle
relaxation in normal tissues in response to endogenous
vasodilators, such as ACh and bradykinin. The NO-donors,
such as sodium nitroprusside (SNP) and the diazeniumdiolate
(or NONOate) NOC-7, are endothelium independent. SNP is
an ion-nitrosyl, which releases NO when it contacts biological
tissue (Bates et al., 1991; Feelisch, 1991). NOC-7 forms one
of a group of compounds, which spontaneously release NO in
aqueous solution (Maragos et al., 1993), NOC-7 having a
half-life of 10.1 min at physiological pH.
Constitutive and inducible isoforms of nitric oxide
synthase (cNOS and iNOS respectively) have been detected
in both experimental and human tumours (Buttery et al.,
1993; Chhatwal et al., 1994; Cobbs et al., 1995; Thomsen et
al., 1994, 1995). Competitive inhibition of NOS, using
analogues of L-arginine at high doses, has been shown to
decrease blood flow and energy status of experimental
tumours and enhance the activity of bioreductive drugs
(Andrade et al., 1992; Tozer et al., 1995; Wood et al., 1993,
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1994). However, the capacity for EDRF production in
tumours is unknown. Any difference from normal would
provide a potential means of selectively modifying tumour
blood flow for therapeutic benefit.
The aims of this study were (1) to determine the sensitivity
of tumour vs normal tissue blood vessels to the vasodilatory
effect of NO; and (2) to determine the capacity of tumour vs
normal tissue endothelial cells for production of EDRF. To
this end, isolated preparations of the rat P22 tumour and
normal rat hindlimb were perfused ex vivo. The effects on
vascular resistance of administration of the NO donors SNP
and NOC-7 (endothelium-independent vasodilators) were
compared with the effects of administration of ACh (an
endothelium-dependent vasodilator) in tumour and normal
tissue. Some of the results for tumour alone have appeared in
preliminary form as part of conference proceedings (Tozer et
al., 1995).
Materials and methods
Tumours
Early generations of the P22 transplanted rat carcinosarcoma
were used for these experiments. Tissue-isolated tumours,
whose vascular supply was derived solely from the superior
epigastric vascular pedicle, were grown in the right inguinal
fat pad of 10 to 11-week-old male BD9 rats. The method
used was essentially as described previously (Tozer et al.,
1994), except that no attempt was made to physically enclose
the growing tumour to prevent vessel ingrowth from
surrounding normal tissue. Instead, the surgically prepared
fat containing a small (approximately 1 mm3) piece of donor
tumour was loosely sutured in position in the inguinal cleft in
order to prevent twisting of the vascular pedicle but allow
movement of the growing tumour within the cleft. This
technique results in a lower incidence of inflammation than
that resulting from enclosure of the growing tumour in silicon
[as used previously (Tozer et al., 1994)], while retaining a
capacity for preventing vessel ingrowth from surrounding
normal tissue. Tumours were used for experimentation when
their vascular supply was seen to derive solely from the
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epigastric vascular pedicle (approximately 50% of prepara-
tions). Tumours were used after 2-3 weeks growth when
they weighed 0.8-2.9 g.
Ex vivo perfusions
The method for ex vivo perfusion of tumours has been
described in detail elsewhere (Tozer et al., 1994). Briefly, rats
were anaesthetised with Hypnorm (Janssen Animal Health,
Oxford, UK) and midazolam (Roche Products, Welwyn
Garden City, UK) and the femoral artery and vein were
catheterised for connection to the perfusion apparatus. All
branching vessels other than the tumour (superior epigastric)
vessels, such as the muscular artery and vein, were ligated or
cauterised. A similar method was employed for the hindlimb
perfusions, except that the femoral vessels were catheterised
proximal rather than distal to the superior epigastric
branching vessels.
Tumours and hindlimbs were perfused with a modified
Krebs -Henseleit (KH) buffer gassed with 5% carbon
dioxide/95% oxygen as described previously (Tozer et al.,
1995). After the start of perfusions, rats were killed by
intravenous administration of Euthatal (RMB Animal
Health, Dagenham, UK) and tissues were left in situ for
the duration of the experiment. A constant perfusate flow
was maintained throughout each experiment and perfusion
pressure was monitored continuously via a physiological
pressure transducer connected to the afferent perfusion line
distal to a bubble trap. Under these conditions perfusion
pressure is directly proportional to vascular resistance. For
tumour preparations, vascular resistance was calculated per
gram of tumour tissue [in (mmHg) (ml g-' min-1)-'] from
perfusion pressure perfusate flow rate per gram of tumour.
However, owing to the efficient collateral blood supply in the
hindlimb of the rat, the volume of tissue perfused in the
normal hindlimb preparations was unknown. Therefore, the
absolute vascular resistance could not be calculated for these
preparations, and drug effects in tumour preparations were
compared with those in hindlimb preparations by comparing
relative changes in vascular resistance measured directly from
changes in perfusion pressure. Increases or decreases in
vascular resistance were taken to represent vasoconstriction
or vasodilation respectively.
Drugs
Drugs were obtained from Sigma Chemical Company, Poole,
UK, unless otherwise stated. Previous results have shown
that blood vessels in ex vivo perfused tumours do not dilate
in response to SNP or ACh unless chemically preconstricted
(Tozer et al., 1995). Normal tissues were not investigated in
this former study. Therefore, all preparations in the present
study, including the hindlimb preparations, were precon-
stricted with phenylephrine (PE, 1 -10 ,UM) or potassium
chloride (KCI, 15-25 mM) by constant infusion into the
afferent perfusate line. This infusion was continued through-
out the time course of the experiment. Doses of PE/KC1 were
adjusted in each preparation in order to achieve approxi-
mately equivalent increases in vascular resistance within the
tumour and normal tissue groups. SNP and ACh were made
up in physiological saline and administered to ex vivo
perfused tumours or hindlimbs by constant infusion into
the perfusate line at concentrations up to 100 /IM. NOC-7
(Alexis Corporation, Nottingham, UK) was made up in
2 mm sodium hydroxide (pH approximately 10) and
administered, in concentrations up to 100 giM, by constant
infusion to ex vivo perfused tumours only. Maximum
concentration of sodium hydroxide after admixture to the
perfusate was 100 gM, which had no effect on tumour
vascular resistance or perfusate pH when administered alone
(results not shown). Escalating doses of SNP and ACh
(approximately 10 min per dose) were administered consecu-
tively to the same tissue preparations with a suitable recovery
period between the two drugs. The order of drug
administration was alternated between preparations. Escalat-
ing doses of NOC-7 (approximately 10 min per dose) were
administered to a separate group of tumours.
Results were expressed as vascular resistance at the end of
each vasodilator drug dose, calculated as a percentage of the
baseline vascular resistance measured following vasoconstric-
tion with PE or KCI. Analysis of variance with repeated
measures followed by a Tukey-Kramer HSD test were used
to test the significance of changes in vascular resistance from
constricted values.
Assay of nitrite/nitrate
In oxygenated aqueous solution, NO is rapidly oxidised
stoichiometrically to nitrite which, in blood, is further
oxidised to nitrate. Thus, measurement of nitrite and nitrate
provides a means of determining changes in NO following
drug treatment in vivo. Samples of effluent perfusate from
tumour preparations were collected from the venous cannula
immediately before drug administration and at the end of the
infusion time for each drug dose and then frozen for
subsequent analysis. Nitrate and nitrite were measured by
anion-exchange chromatography using a method similar to
that described previously (Everett et al., 1995), except that
nitrite was determined by electrochemical detection (Stratford
et al., 1996). Analysis of variance with repeated measures
followed by a Tukey-Kramer HSD test were used to test
significance of changes in nitrite concentration from
constricted values.
Results
The vasodilators, SNP and ACh, had no effect on vascular
resistance of ex vivo perfused normal hindlimbs or tumours
unless the baseline perfusion pressure was raised by
administration of PE or KCI. This has been reported
previously for tumours (Tozer et al., 1995). Figure 1 shows
the vasoactive effects of SNP and ACh in normal hindlimbs
following preconstriction with PE/KC1. Both SNP and ACh
produced the expected vasodilation, as shown by a significant
decrease in vascular resistance in each case. Vascular
resistances at 1 pM SNP and above were significantly
different from control values (P<0.01) and all doses were
significantly different from each other (P<0.05), except for 1
and 10 gM. Similarly vascular resistances at 0.1 gM ACh and
above were significantly different from control values
(P<0.01), but the dose-response was shallower than that
for SNP with no significant difference at the 5% level
between vascular resistance measured at 0.1, 1 and 10 gM
ACh.
Tumour vascular resistance measured ex vivo at the start
of each experiment was 229 + 30 resistance units for the SNP/
ACh group and 231 + 31 resistance units for the NOC-7
group [1 resistance unit = 1 (mmHg) (ml g- ' min- ')- ']. PE/
KCI increased these values to 371 + 42 and 412 + 42 resistance
units for the SNP/ACh and NOC-7 groups respectively. A
feature of the tumour perfusions, but not the normal
hindlimb perfusions, was a constrictor-induced oscillation in
perfusion pressure. This has been reported previously for PE
(Tozer et al., 1995) and was observed in the present study for
both PE and KCI, drugs which vasoconstrict via different
mechanisms. Figure 2a shows an example of oscillations in
perfusion pressure induced by KCI and the subsequent effect
of SNP infusion. Since perfusate flow was kept constant, the
oscillations directly represent changes in vascular resistance.
In this tumour, doses of 10 puM SNP and above vasodilated,
as shown by the reduction in perfusion pressure. Generally,
SNP was also observed to reduce the amplitude of
oscillations and, in the specific case shown in Figure 2a, the
oscillations disappeared at high SNP doses. Figure 2b shows
a similar recording of PE-induced oscillations during ACh
infusion. In this case, the oscillations only became apparent
after the start of ACh infusion. Low doses of ACh had very
little effect on mean perfusion pressure, but there was a small
increase in perfusion pressure at 100 pM, the highest dose
used. There is some indication in Figure 2b that the highest
doses of ACh reduced the amplitude of oscillations, but this
was generally less apparent than for SNP. Oscillatory changes
in vascular resistance have also been reported for arteries
supplying the P22 tumour growing in the inguinal fat pad
(Kennovin et al., 1994) but, at present, there is no
explanation for this effect. During the oscillatory phases,
the mean perfusion pressure used for calculation of vascular
resistance was determined from the mid-point between peaks
and troughs in the recording.
Comparison of the effects of the vasodilators SNP and
ACh on mean tumour vascular resistance is shown in Figure
3a and b. SNP produced the expected vasodilation, as shown
by a significant decrease in vascular resistance. However,
ACh, unlike the effect in normal hindlimb under the same
experimental conditions, produced an anomalous increase in
vascular resistance indicative of vasoconstriction. The
decrease with SNP was significantly different from control
at 10 and 100 pM (P<0.01), and the increase with ACh was
significantly different from control at 1, 10 and 100 gM
(P<0.01). A dose-response for SNP is suggested by a
significant difference in tumour vascular resistance at 10 and
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100 gM SNP (P<0.01) and for ACh in which tumour
vascular resistance at 100 gM ACh was significantly different
from that at all other doses (P<0.01).
Mean nitrate and nitrite concentrations in the efferent
perfusate of untreated tumours were 21.3 + 3.0 gIM and
0.35+0.09 giM respectively. Throughout these experiments,
no changes were observed in the nitrate concentration (results
not shown), presumably owing to the absence of haemoglo-
bin in the perfusate precluding futher oxidation. Nitrite levels
in the efferent tumour perfusate significantly increased with
SNP administration (Figure 3c), but remained unchanged
during ACh administration (Figure 3d). The SNP result is
consistent with a release of NO from SNP when it contacts
biological material (Bates et al., 1991; Feelisch, 1991) and the
observed tumour vasodilation (Figure 3a). The ACh result
indicates that an insignificant amount of NO (EDRF) was
released from tumour endothelial cells in response to ACh
and this is consistent with an absence of any tumour
vasodilation (Figure 3b). For SNP, only the 100 jgM dose
produced significantly higher nitrite in the efferent perfusate
compared with the control level (P<0.001), whereas changes
in vascular resistance were significant for both 10 and
100 gM. This indicates that the nitrite assay is rather
insensitive to changes in NO that can elicit a biological
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Figure 1 Relative changes in tissue vascular resistance in normal
rat hindlimbs following administration of (a) sodium nitroprus-
side (SNP) and (b) acetyicholine (ACh). 100% represents vascular
resistance during constriction with PE/KCI. Symbols are
means + 1 s.em., up to six preparations per point. The shaded
area represents the mean vascular resistance+ 1 srem. before
constriction with PE/KCI. Significant differences from control are
indicated by *(P<0.01) and **(P<0.001).
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Figure 2 Oscillations in tumour perfusion pressure during ex
vivo perfusion of two tumours (a and b). Graphs show parts of
the time course of perfusion for each tumour. The tumour in a
was vasoconstricted with potassium chloride throughout the time
course shown and arrows indicate the start of SNP infusion of
escalating concentrations. The tumour in b was vasoconstricted
with PE throughout the time course shown and arrows indicate
the start of ACh infusion at escalating concentrations.
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Figure 3 Relative changes in tissue vascular resistance and efferent nitrite levels of isolated perfused P22 rat tumours following
administration of sodium nitroprusside (SNP) (a and c) and acetylcholine (ACh) (b and d). 100% represents vascular resistance/
nitrite concentration during constriction with PE/KCI. Symbols are means + 1 s.e.m., up to nine preparations per point. The shaded
area in a and b represents the mean vascular resistance + 1 s.e.m. before constriction with PE/KCI. Siginificant differences from
control are indicated by *(P<O.Ol) and **(P<0.o0l1).
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Figure 4 Relative changes in tissue vascular resistance of isolated
perfused P22 rat tumours following administration of NOC-7.
100% represents vascular resistance during constriction with PE3/
KCI. Symbols are means+±I s.e.m., up to six preparations per
point. The shaded area represents the mean vascular resistance +
s.e.m. before constriction with PE/KCI. Significant differences
from control are indicated by **(P<0.o001).
effect. SNP in aqueous solution had no effect on the nitrite
assay at the doses used (results not shown). For ACh, no
significant changes in nitrite concentration, at the 5% level,
were observed at any dose used.
Figure 4 shows that the NO-donor NOC-7 is also an
effective dilator of tumour blood vessels. The decrease in
vascular resistance was significant at 1 pm and above
(P <0.001). A dose-response is suggested by a significant
difference between vascular resistance measured at 0.1 gm
compared with 1 and 10 gm NOC-7 (P <0.05). Comparison
of Figures 3 and 4 shows that NOC-7 is more effective as a
dilator of tumour blood vessels than SNP on an equimolar
basis. This is consistent with a very efficient release of NO
from NOC-7 and other diazeniumdiolates (Maragos et al.,
1993).
Discussion
The normal rat hindlimb, perfused ex vivo, vasodilated in
response to both SNP and ACh, as shown by a decrease in
vascular resistance in each case. This was the expected result
from numerous reports in the literature for normal rat
hindlimb and other normal tissues perfused under similar
conditions. The P22 tumour, perfused ex vivo, vasodilated in
response to SNP and NOC-7, but not in response to ACh.
Indeed, a small vasoconstriction, as shown by an increase in
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vascular resistance, was observed in the tumour at the highest
ACh dose used. The tumour response to ACh was
unexpected and, since ACh vasodilates primarily via
endothelial release of NO (EDRF), suggests a defect in the
tumour vasculature at the level of the endothelium. It is well
established that tumour blood vessels differ from normal
blood vessels in terms of the proliferative capacity of their
endothelial cells (Denekamp and Hobson, 1982) and their
permeability (Dvorak et al., 1991). Capacity for production
of EDRF may represent a third difference, which could be
exploited for selective chemical manipulation of tumour
blood flow.
Muscarinic receptors for ACh exist on vascular smooth
muscle cells as well as on endothelial cells. In the presence of
an intact, functional endothelium, the overwhelming response
to exogenously administered ACh is vasodilation resulting
from release of EDRF following muscarinic receptor
activation of the endothelium. However, in the case of an
incomplete or dysfunctional endothelium, activation of
receptors on vascular smooth muscle can dominate and
result in vasoconstriction (Ralevic and Burnstock, 1993). This
phenomenon would explain the vasoconstrictive effect of
ACh in our tumours.
There are many processes along the pathway for EDRF
production following ACh administration, which could be
deficient in tumours. It is not known, for instance, whether
tumour endothelial cells lack muscarinic receptors or whether
there is a deficiency in the enzyme biochemistry of cNOS.
Using immunohistochemistry, cNOS has been identified in
some human tumours (Cobbs et al., 1995; Thomsen et al.,
1994, 1995), but not in some other tumour systems (Buttery
et al., 1993). However, it is not known whether any of these
tumours are capable of EDRF production following receptor
activation of the endothelium. In some vascular beds, part of
the ACh-induced vasodilation appears to unrelated to NO
(Zygmunt et al., 1994), such that part of the tumour
deficiency noted here may be the same. For example, a
component of ACh-induced vasodilation has been attributed
to prostacyclin, an NO-independent hyperpolarising factor or
carbon monoxide formed from haemoxygenase (Poston and
Taylor, 1995).
A deficient vasodilatory response to ACh has also been
reported for isolated arteries/arterioles from diabetic rats
perfused ex vivo. Poston and Taylor (1995) have discussed
possible artefacts in the systems used for these studies but
conclude that the balance of the evidence is for a
compromised capacity of the endothelium to relax the
adjacent vascular smooth muscle in diabetes. Currently,
there are no other investigations of EDRF activity in ex
vivo perfused tumours for comparison with our results. The
PE/KC1 induced oscillations in vascular resistance of our
perfused tumours may represent a perfusion artefact,
indicative of vascular damage, which could be the cause of
the anomalous response of the tumour vasculature to ACh. It
is known, for instance, that endothelial cell function is
particularly sensitive to damage from ischaemia followed by
reperfusion (Sternbergh et al., 1992), which could occur
during the surgical procedure. However, such an explanation
would require that the tumour preparations were more prone
to this type of injury than normal hindlimb preparations,
which also underwent surgery but did vasodilate in response
to ACh. The fact that SNP reduced the amplitude of
oscillations observed in the tumour perfusions suggests that
the oscillations resulted from interference with NO produc-
tion in some way, which was counteracted by NO released
from SNP. Both KCl and PE induced oscillations in tumour
vascular resistance. KCl vasoconstricts via direct depolarisa-
tion of the vascular smooth muscle cell membrane, which
causes activation of voltage-gated calcium channels (VGCs)
and a consequent rise in intracellular calcium. PE
vasoconstricts via x-adrenergic receptor activation on
vascular smooth muscle cells, which results in an increase
in free intracellular calcium via membrane depolarisation and
activation of VGCs, activation of receptor-operated calcium
channels and G-protein-mediated activation of phospholipase
C (Levick, 1992). Therefore, there is a component of PE-
induced vasoconstriction, which acts in the same way as KCl,
but there are also major differences in the mode of action of
the two vasoconstrictors. Futher experiments with different
vasoconstrictors would be required to determine whether it is
the mechanism of vasoconstriction or the consequent increase
in perfusion pressure that induces the oscillatory behaviour in
the tumour preparations. Whatever the cause, the oscillations
highlight some difference between tumour and normal tissue
vasculature, which warrants futher investigation and could be
exploited.
Currently, we are testing the in vivo response of the P22
tumour to the vasodilatory drugs tested here. If a defect in
tumour EDRF production is established in vivo, it suggests a
strategy for selective tumour blood flow modification.
Vasodilators, such as hydralazine, can cause vascular
shutdown in tumours, which potentiates the cytotoxicity of
bioreductive drugs (Chaplin, 1989; Chaplin and Acker, 1987).
This is presumably a result of hypotension combined with
minimal dilation of tumour blood vessels which appear to be
maximally dilated under in vivo conditions (Peterson, 1991).
However, mean arterial blood pressure needs to be reduced
below clinically feasible levels to obtain this effect (Horsman
et al., 1992). It is conceivable that, if ACh (or a related
compound) induces tumour vasoconstriction in vivo, then a
significant reduction in tumour blood flow could be obtained
at moderate levels of hypotension. This strategy warrants
investigation.
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